accounta program for the once-monthly drug. That leaves Alkermes' future squarely on the shoulders of Amylin Pharmaceuticals' and Eli Lilly's once-weekly Byetta, which is under review with the Food and Drug Administration. Last up is Flamel Technologies...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to 4 Platform Drugmakers to Invest In
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account